Re­genxbio shares new mid-stage da­ta for its wet AMD gene ther­a­py

Re­genxbio re­leased pos­i­tive new da­ta from a Phase 2 tri­al in­ves­ti­gat­ing its ex­per­i­men­tal one-time gene ther­a­py for bi­lat­er­al wet age-re­lat­ed mac­u­lar de­gen­er­a­tion (wet AMD). …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER